Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer

Japanese Journal of Clinical Oncology

Volumn 40, Issue 10, 2010, Pages 913-920

  Doi, Toshihiko ^a   Boku, Narikazu ^b   Kato, Ken ^c   Komatsu, Yoshito ^d   Yamaguchi, Kensei ^e   Muro, Kei ^f   Hamamoto, Yasuo ^g   Sato, Atsushi ^h   Koizumi, Wasaburo ⁱ   Mizunuma, Nobuyuki ^j   Takiuchi, Hiroya ^k  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g TOCHIGI CANCER CENTER   (Japan)

^h SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j CANCER INSTITUTE HOSPITAL   (Japan)

^k OSAKA MEDICAL COLLEGE HOSPITAL   (Japan)

more..

Author keywords

Bevacizumab; Colorectal cancer; Japanese; Xelox

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMATOLOGICAL TOXICITY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROSENSORY TOXICITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANOREXIA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; JAPAN; MALE; MIDDLE AGED; NAUSEA; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SENSATION DISORDERS; TREATMENT OUTCOME;

EID: 77957709580     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq069     Document Type: Article

References (31)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. American Cancer Society, Cancer statistics 2004. CA Cancer J Clin 2004;54:8-29.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
3. Cancer Statistics in Japan Editorial Board. Cancer Statistics in Japan 2009. Foundation for Promotion of Cancer Research; 2009.
4. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
5. Goldberg RM, Morton RF, Sargent DJ, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
6. VanCutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001;19:4097-106.
7. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004;90:1190-7.
8. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
9. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.
10. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91.
11. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008;19:1720-6.
12. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-12.
13. Saltz L, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
14. Díaz-Rubio E, Evans TR, Tabemero J, Cassidy J, Sastre J, Eatock M, et al. Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002;13:558-65.
15. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
16. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93.
17. National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTC Version 3.0, 31 March 2003).
18. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
19. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523-2539.
20. Berry SR, Van Cutsem E, Kretzschmar A, Michael M, Rivera F, DiBartolomeo M, et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. J Clin Oncol 2008;26(Suppl.; abstr 4025).
21. Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn PJ, Dong W, et al. Survival of patients (pts) with mCRC treated with bevacizumab in combination with chemotherapy: Results from the BRiTE registry. Presented at the ASCO GI Cancers Symposium, 19-21 January 2007 (abstr 375).
22. Reinacher-Schick AC, Kubicka S, Freier W, Arnold D, Dietrich G, Geissler M, et al. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol 2008;26(Suppl.; abstr 4030)
23. Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Presented at the ASCO GI Cancers Symposium 2007 (abstr 238).
24. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. XELOX-1/NO16966, a randomized phase III trial of first-line XELOX compared with FOLFOX4 for patients with metastatic colorectal cancer (MCRC); Updated survival and tolerability results. Presented at the ASCO GI Cancers Symposium 2009; (abstr 382).
25. Hyodo I, Shirao K, Doi T, Hatake K, Arai Y, Yamaguchi K, et al. A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2006;36:410-7.
26. Rothenberg ML, Saltz L, Cunningham D, Cassidy J, Diaz-Rubio E, Scheithauer W, et al. Tolerability of fluoropyrimidines in combination with oxaliplatin appears to differ by region. Presented at the ASCO GI Cancers Symposium, 25-27 January 2008 (abstr 456).
27. Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, et al. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. Jpn J Clin Oncol 2007;37:686-91.
28. Shirao K, Hoff P, Ohtsu A, Loehrer P, Hyodo I, Wadler S, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/ tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 2004;22:3466-74.
29. Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;26:2118-23.
30. NCCN Clinical Practice Guidelines in Oncology, colon cancer, v.3. 2009.
31. Ducreux M, Bennouna J, Hebber M, Ychou M, Lledo G, Conroy T, et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 2007;25(Suppl.; abstr 4029).